BRITISH JOURNAL OF HAEMATOLOGY

Scope & Guideline

Transforming Hematology Through Rigorous Research

Introduction

Explore the comprehensive scope of BRITISH JOURNAL OF HAEMATOLOGY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore BRITISH JOURNAL OF HAEMATOLOGY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0007-1048
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1955 to 2024
AbbreviationBRIT J HAEMATOL / Br. J. Haematol.
Frequency23 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The British Journal of Haematology aims to publish high-quality research that enhances the understanding and treatment of blood disorders, including various leukaemias, lymphomas, myelomas, and other haematological conditions. The journal encompasses a wide range of topics from basic research to clinical applications, providing an essential platform for disseminating new findings and therapeutic strategies.
  1. Clinical Trials and Treatment Efficacy:
    The journal frequently publishes results from clinical trials and observational studies that assess the efficacy and safety of new treatments for haematological malignancies, including novel agents like CAR T-cell therapies, targeted therapies, and immunotherapies.
  2. Transfusion Medicine and Blood Disorders:
    Research on transfusion practices, complications, and management of blood disorders such as sickle cell disease, thalassaemia, and immune thrombocytopenia is a core focus area, addressing both clinical and logistical aspects of transfusion medicine.
  3. Molecular and Genetic Insights:
    The journal emphasizes studies that explore the molecular and genetic basis of haematological diseases, including the impact of specific mutations on prognosis and treatment response, integrating genomics with clinical outcomes.
  4. Patient-Centered Outcomes:
    There is a strong emphasis on patient-reported outcomes and quality of life assessments in patients with haematological conditions, highlighting the importance of treatment impact on patients' daily lives.
  5. Guidelines and Best Practices:
    The journal serves as a platform for disseminating guidelines and consensus statements from leading haematology societies, ensuring that practitioners have access to the latest recommendations for diagnosis and management.
The British Journal of Haematology is at the forefront of emerging trends in haematology research, reflecting advancements in technology, therapy, and patient care. Recent publications highlight several key themes that are gaining traction within the field.
  1. Novel Immunotherapies and CAR T-Cell Therapies:
    There is a growing body of research focused on innovative immunotherapies, particularly CAR T-cell therapies, which are being extensively studied for their efficacy in treating various haematological malignancies.
  2. Real-World Data and Observational Studies:
    An increasing number of publications emphasize the importance of real-world evidence and observational studies, providing insights into treatment effectiveness and patient outcomes in everyday clinical settings.
  3. Genomic and Precision Medicine:
    Research into genomic profiling and precision medicine is on the rise, with studies exploring how genetic mutations and biomarkers can inform tailored treatment approaches for individual patients.
  4. Impact of COVID-19 on Haematology Patients:
    The journal has seen a surge in studies assessing the impact of COVID-19 on patients with haematological conditions, including the effects on treatment protocols and patient outcomes.
  5. Patient-Centric Research and Quality of Life Studies:
    There is an emerging trend towards research that prioritizes patient perspectives, including quality of life assessments and patient-reported outcomes, recognizing the importance of holistic care in managing haematological diseases.

Declining or Waning

While the British Journal of Haematology continues to cover a broad range of topics, certain areas of research have seen a decline in focus over the years. This may reflect shifts in clinical priorities or the completion of research cycles in these domains.
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable decline in publications focused solely on traditional chemotherapy regimens for haematological malignancies, as the field increasingly shifts towards targeted therapies and immunotherapies that promise improved outcomes.
  2. Longitudinal Studies of Established Therapies:
    Research on the long-term outcomes of established therapies such as older chemotherapeutic agents has decreased, likely due to the emergence of new treatment modalities that attract more research interest.
  3. Generalized Studies Without Specific Focus:
    There appears to be less emphasis on broad, generalized studies that do not target specific haematological conditions or interventions, as the field gravitates towards more precise and targeted research.
  4. Classic Transfusion Practices:
    Although transfusion medicine remains a significant area of focus, the exploration of classic transfusion practices is waning, with more attention being given to innovative transfusion strategies and technologies.
  5. Historical Perspectives on Haematology:
    Papers focusing on historical aspects of haematology or retrospective analyses of outdated treatments are becoming less common, indicating a shift towards contemporary research that addresses current challenges.

Similar Journals

BLOOD

Connecting Scholars, Advancing Knowledge in Blood Research.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

LEUKEMIA

Your Premier Source for Leukemia Research
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Indian Journal of Hematology and Blood Transfusion

Fostering Collaboration in Hematology and Transfusion Medicine
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

AMERICAN JOURNAL OF HEMATOLOGY

Elevating Knowledge in Blood Health and Treatment
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Therapeutic Advances in Hematology

Transforming research into impactful therapies.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

TRANSFUSION AND APHERESIS SCIENCE

Fostering Collaboration and Innovation in Blood Health
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 1473-0502Frequency: 6 issues/year

TRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.

EUROPEAN JOURNAL OF HAEMATOLOGY

Elevating Knowledge in Hematology Since 1986
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Blood Cancer Discovery

Illuminating the Path to Understanding Blood Malignancies
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Egyptian Journal of Haematology

Empowering Hematologists with Cutting-Edge Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Blood Science

Exploring the Frontiers of Blood Science
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.